Recombinant Human Erythropoietin vs Transfusions in the Treatment of Anemia of Prematurity
- 1 June 1994
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Pediatrics & Adolescent Medicine
- Vol. 148 (6) , 582-588
- https://doi.org/10.1001/archpedi.1994.02170060036006
Abstract
Research from JAMA Pediatrics — Recombinant Human Erythropoietin vs Transfusions in the Treatment of Anemia of Prematurity — A Cost-benefit AnalyisKeywords
This publication has 11 references indexed in Scilit:
- The Risk of Transfusion-Transmitted InfectionNew England Journal of Medicine, 1992
- Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infantsThe Journal of Pediatrics, 1992
- Principles of Pharmacoeconomic Analysis of Drug TherapyPharmacoEconomics, 1992
- Recombinant erythropoietin compared with erythrocyte transfusion in the treatment of anemia of prematurityThe Journal of Pediatrics, 1991
- Transfusion Therapy in NeonatesArchives of Pediatrics & Adolescent Medicine, 1991
- Use of Recombinant Erythropoietin in Treatment of the Anemia of PrematurityJournal of Pediatric Hematology/Oncology, 1991
- Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the “anemia of prematurity”The Journal of Pediatrics, 1988
- Reducing the incidence of non-A, non-B post-transfusion hepatitis by testing donor blood for alanine aminotransferase: Economic considerationsJournal of Oral and Maxillofacial Surgery, 1983
- The Distinction Between Cost and ChargesAnnals of Internal Medicine, 1982
- Prevention of transfusion-acquired cytomegalovirus infections in newborn infantsThe Journal of Pediatrics, 1981